Darren D O'rielly

List of Publications by Year
in descending order

40 papers	663 citations	567281 15 h-index	610901 24 g-index
40 all docs	40 docs citations	40 times ranked	1186 citing authors

#	Article	IF	Citations
1	Genetics of susceptibility and treatment response in psoriatic arthritis. Nature Reviews Rheumatology, 2011, 7, 718-732.	8.0	55
2	Genetic, Epigenetic and Pharmacogenetic Aspects of Psoriasis and Psoriatic Arthritis. Rheumatic Disease Clinics of North America, 2015, 41, 623-642.	1.9	50
3	Inhibition of Spinal Prostaglandin Synthesis Early after L5/L6 Nerve Ligation Prevents the Development of Prostaglandin-dependent and Prostaglandin-independent Allodynia in the Rat. Anesthesiology, 2003, 99, 1180-1188.	2.5	41
4	Extending the scope of diagnostic chromosome analysis: Detection of single gene defects using high-resolution SNP microarrays. Human Mutation, 2011, 32, 1500-1506.	2.5	41
5	Increased Expression of Cyclooxygenase and Nitric Oxide Isoforms, and Exaggerated Sensitivity to Prostaglandin E2, in the Rat Lumbar Spinal Cord 3 Days after L5â€“L6 Spinal Nerve Ligation. Anesthesiology, 2006, 104, 328-337.	2.5	40
6	Genetics of psoriatic arthritis. Best Practice and Research in Clinical Rheumatology, 2014, 28, 673-685.	3.3	39
7	The Genetics of Psoriasis and Psoriatic Arthritis. Journal of Rheumatology, 2019, 95, 46-50.	2.0	38
8	Pharmacogenetics of psoriasis. Pharmacogenomics, 2011, 12, 87-101.	1.3	24
9	Complexities in Genetics of Psoriatic Arthritis. Current Rheumatology Reports, 2020, 22, 10.	4.7	23
10	Ankylosing spondylitis: beyond genome-wide association studies. Current Opinion in Rheumatology, 2016, 28, 337-345.	4.3	22
11	Integrated Genomics Identifies Convergence of Ankylosing Spondylitis with Global Immune Mediated Disease Pathways. Scientific Reports, 2015, 5, 10314.	3.3	20
12	Quantifying Differences in Heritability among Psoriatic Arthritis (PsA), Cutaneous Psoriasis (PsC) and Psoriasis vulgaris (PsV). Scientific Reports, 2020, 10, 4925.	3.3	20
13	UGT2B17 copy number gain in a large ankylosing spondylitis multiplex family. BMC Genetics, 2013, 14, 67.	2.7	19
14	Pharmacogenetics and pharmacogenomics in psoriasis treatment: current challenges and future prospects. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 923-935.	3.3	17
15	Private rare deletions in SEC16A and MAMDC4 may represent novel pathogenic variants in familial axial spondyloarthritis. Annals of the Rheumatic Diseases, 2016, 75, 772-779.	0.9	17
16	A review of ustekinumab in the treatment of psoriatic arthritis. Immunotherapy, 2018, 10, 361-372.	2.0	15
17	Genome-Wide Signatures of â€˜Rearrangement Hotspotsâ€™ within Segmental Duplications in Humans. PLoS ONE, 2011, 6, e28853.	2.5	14
18	A common variant in CLDN14 causes precipitous, prelingual sensorineural hearing loss in multiple families due to founder effect. Human Genetics, 2017, 136, 107-118.	3.8	14

#	Article	IF	Citations
19	Psoriatic arthritis: genetic susceptibility and pharmacogenetics. Pharmacogenomics, 2008, 9, 195-205.	1.3	13
20	A review of ixekizumab in the treatment of psoriatic arthritis. Expert Review of Clinical Immunology, 2018, 14, 993-1002.	3.0	12
21	Advances in the Genetics of Spondyloarthritis and Clinical Implications. Current Rheumatology Reports, 2013, 15, 347.	4.7	11
22	Spinal Prostaglandins Facilitate Exaggerated A- and C-fiber-mediated Reflex Responses and Are Critical to the Development of Allodynia Early after L5-L6 Spinal Nerve Ligation. Anesthesiology, 2007, 106, 795-805.	2.5	11
23	Ustekinumab in psoriatic arthritis and related phenotypes. Therapeutic Advances in Chronic Disease, 2018, 9, 191-198.	2.5	10
24	Novel Usher syndrome pathogenic variants identified in cases with hearing and vision loss. BMC Medical Genetics, 2019, 20, 68.	2.1	10
25	The genetic architecture of Stargardt macular dystrophy (STGD1): a longitudinal 40-year study in a genetic isolate. European Journal of Human Genetics, 2020, 28, 925-937.	2.8	10
26	Pharmacogenetics of rheumatoid arthritis: Potential targets from susceptibility genes and present therapies. Pharmacogenomics and Personalized Medicine, 2010, 3, 15.	0.7	8
27	Whole exome sequencing uncovered highly penetrant recessive mutations for a spectrum of rare genetic pediatric diseases in Bangladesh. Npj Genomic Medicine, 2021, 6, 14.	3.8	8
28	A pathogenic deletion in Forkhead Box L1 (FOXL1) identifies the first otosclerosis (OTSC) gene. Human Genetics, 2022, 141, 965-979.	3.8	7
29	Mutational Landscape of Autism Spectrum Disorder Brain Tissue. Genes, 2022, 13, 207.	2.4	7
30	Autosomal dominant non-syndromic hearing loss maps to DFNA33 (13q34) and co-segregates with splice and frameshift variants in ATP11A, a phospholipid flippase gene. Human Genetics, 2022, 141, 431-444.	3.8	7
31	A dominant RAD51C pathogenic splicing variant predisposes to breast and ovarian cancer in the Newfoundland population due to founder effect. Molecular Genetics & Genomic Medicine, 2020, 8, e1070.	1.2	6
32	An Exploration of Physical and Phenotypic Characteristics of Bangladeshi Children with Autism Spectrum Disorder. Journal of Autism and Developmental Disorders, 2021, 51, 2392-2401.	2.7	6
33	Expression and Metabolomic Profiling in Axial Spondyloarthritis. Current Rheumatology Reports, 2018, 20, 51.	4.7	5
34	Rho-GTPase pathways may differentiate treatment response to TNF-alpha and IL-17A inhibitors in psoriatic arthritis. Scientific Reports, 2020, 10, 21703.	3.3	5
35	Clinical and molecular significance of genetic loci associated with psoriatic arthritis. Best Practice and Research in Clinical Rheumatology, 2021, 35, 101691.	3.3	5
36	High Accuracy and Significant Savings Using Tag-SNP Genotyping to DetermineHLA-B*27Status. Journal of Rheumatology, 2017, 44, 962.2-963.	2.0	5

#	Article	IF	Citations
37	Genetic Epidemiology of Complex Phenotypes. Methods in Molecular Biology, 2021, 2249, 335-367.	0.9	3
38	Evaluation for Psoriatic Arthritis in Dermatology Clinics. Journal of Cutaneous Medicine and Surgery, 2009, 13, S88-S92.	1.2	2
39	Real-world Experience of Using HLA-B*27 Tag-single-nucleotide Polymorphism Assay to Screen for Axial Spondyloarthritis. Journal of Rheumatology, 2018, 45, 1712-1712.	2.0	2
40	Powered for Success: Considerations for Using the Candidate Gene Approach in Rheumatic Diseases in the Post-genomics Era. Journal of Rheumatology, 2014, 41, 1573-1575.	2.0	1